In this episode, we’re talking about some issues with treatments. We’re looking at some drugs that have lost or might lose their approvals, or cases where additional measures are put in place for safety reasons. 

Here are some resources or references used in the research for this episode - 

Crizanlizumab statement. January 2024 » Sickle Cell Society

Crizanlizumab - end of NHS supply » Sickle Cell Society

FDA starts speedy review of Novartis’ sickle cell antibody - PMLiVE

Exa-Cel (Casgevy) Gene Therapy Update » Sickle Cell Society

Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions - GOV.UK (www.gov.uk)

Remember, you can get in touch with us via [email protected]. Please feel free to send questions, comments and compliments for Elyse to read out on the pod. It’s fun to make Debbie squirm!

Credit to our friend Sam Winnie for their awesome and cute music. Check out their work at https://www.samwinnie.com/